CTCAE Grading System for Adverse Events in Cancer Treatment

Introduction to CTCAE

The National Cancer Institute developed the Common Terminology Criteria for Adverse Events (CTCAE) as a standardized, numeric grading system (Grades 1-5) to classify and report the severity of adverse effects from cancer treatments, combining both objective clinical measurements and subjective patient symptoms 1, 2

The CTCAE system operates on a 5-point severity system, with Grade 1 being a mild adverse event 3, Grade 2 being a moderate adverse event 3, and Grade 3 being a severe adverse event 4

The CTCAE combines objective threshold measurements with subjective clinical assessments to assign severity grades, and is used by clinicians to document treatment toxicities, monitor side effects, and guide treatment modifications 1, 2
The CTCAE system has recognized deficiencies, including under-reporting of clinically significant toxicity, particularly in pediatric populations 2, 6, and coarse grading at higher severity levels, with Grades 2 and 3 being too broadly defined 2
The system also has limited specificity for certain toxicities, such as ototoxicity, where CTCAE diverges from therapeutic recommendations at higher grades 3, 4
The FDA uses CTCAE and patient-reported outcome versions (CTCAE-PROs) to monitor treatment side effects systematically 5

CTCAE is primarily a clinician-based reporting system, but the FDA increasingly uses CTCAE and patient-reported outcome versions (CTCAE-PROs) to monitor treatment side effects systematically 5
Systematic evaluation using validated measurement tools allows robust statistical analysis of adverse events 5
The National Cancer Institute recommends using both CTCAE and PRO-CTCAE to refine understanding of lower-grade adverse events that can lead to treatment discontinuation and diminished quality of life 5